Medly, a London-based education technology company, has raised $8 million — approximately €6.9 million — in a Seed round led by Felix Capital, with participation from Eka Ventures and Ada Ventures.
The company was founded by Dr Paul Jung and Dr Kavi Samra and builds an AI platform that delivers personalised tutoring to secondary-school students, covering GCSE, IGCSE, A-Level and International Baccalaureate curricula.
The product and the claim
Medly's proposition is adaptive one-to-one support: content and questioning that adjust to an individual student's demonstrated understanding rather than following a fixed sequence. Its Medly Open initiative extends access beyond the paid product.
The company states that it has more than 400,000 users in the United Kingdom. That figure is company-reported and has not been independently verified here. It has also received a grant under the Department for Education's AI Tutoring Tools Pioneers Programme — a public procurement signal that carries some weight, though it is a grant for exploration rather than an endorsement of learning outcomes.
Evidence is the open question
New funding is directed at international expansion, including the United States, and at building research and evidence around the product's effectiveness.
That second workstream is the one that matters most. Educational technology has a long record of adoption running ahead of demonstrated impact, and the sector's credibility with schools, regulators and parents increasingly depends on measured attainment rather than engagement metrics. Companies that invest early in independent evaluation are making a bet that procurement will eventually be evidence-led — a reasonable assumption in state education, where budgets are scrutinised and results are published.
The commercial logic of AI tutoring is straightforward enough. Human one-to-one tuition produces strong outcomes and is priced accordingly, which restricts it to families who can afford it. Software that approximates part of that experience at near-zero marginal cost addresses both a large consumer market and an equity argument that appeals to public buyers. The unresolved question is how much of the benefit of a skilled human tutor actually transfers.
Why the sector is being funded again
Investor appetite for education technology cooled after the pandemic-era surge, when usage receded and several highly valued businesses struggled to convert trial users into durable revenue. The current wave is being underwritten on a different basis: capability that did not previously exist, rather than distribution to a temporarily captive audience.
For allocators, the risks remain distinctive. Sales into schools are slow and budget-bound; consumer subscriptions in education churn seasonally around examinations; and international expansion is complicated by curricula that differ country by country, requiring genuine content work rather than translation. US entry, in particular, means building for a fragmented state-by-state standards landscape.
Distribution is the other unresolved variable. A product used directly by students builds awareness quickly but monetises through parents, while institutional sales to schools convert more slowly and at lower prices per user but produce far more predictable renewals. Companies that attempt both simultaneously frequently find the two motions require different organisations.
Medly has not published a valuation, revenue figures or attainment data alongside the round.
UKFOS editorial · published 23 August 2026